Monitored anaesthesia care with remifentanil vs anaesthesia with propofol-alfentanil for ultrasound guided transvaginal oocyte retrieval: effect on fertilization rate, cleavage rate, implantation rate and pregnancy rate

2006 ◽  
Vol 23 (Supplement 37) ◽  
pp. 161
Author(s):  
P. Matsota ◽  
C. Batistaki ◽  
K. Christodoulaki ◽  
A. Pandazi ◽  
I. Grigoropoulou ◽  
...  
1994 ◽  
Vol 6 (1) ◽  
pp. 45 ◽  
Author(s):  
D Payne ◽  
GM Warnes ◽  
SP Flaherty ◽  
CD Matthews

Clinical trials were performed between 1987 and 1992 on the use of zona drilling (ZD), zona cutting (ZC) and subzonal sperm microinjection (SZI) for the treatment of severe male infertility. ZD significantly improved the fertilization rate, but embryo morphology was poor and no pregnancies were achieved, so it was abandoned in favour of ZC. The fertilization rate was acceptable in the first trial of ZC but embryo morphology was still poor and no pregnancies were achieved, so a number of protocol changes were instigated. Shrinkage of oocytes in hypertonic sucrose prior to ZC markedly improved embryo quality, whereas transfer of embryos on Day 3 after oocyte retrieval enhanced the pregnancy rate. However, despite these improvements, the overall pregnancy rate in the third ZC trial was still low (16.6% per transfer), so a trial of SZI was initiated in 1992. The overall fertilization rate in 82 SZI cycles was 34.4% and, although the polyspermy rate was high, a clinical pregnancy rate of 30.8% per transfer and an implantation rate of 18.4% per embryo were achieved. These trials demonstrate that SZI is a successful treatment for severe male infertility; under the trial conditions, at least, it was superior to ZD or ZC.


2021 ◽  
Author(s):  
Weihai Xu ◽  
Lin Zhang ◽  
Ling Zhang ◽  
Shishi Li ◽  
Jing Shu

Abstract Background: In this study, we compared the in vitro embryo development, embryo transfer outcome and the offspring outcome in the in vitro fertilization-embryo transfer (IVF-ET) between dry culture (DC) and humid culture (HC). Methods: Our study was divided into two parts. Firstly, we determined the fertilization rate, cleavage rate and high-quality embryo rate from 21 cycles in the DC group (N=262 oocytes) and HC group (N=263 oocytes). Secondly, we determined the embryo transfer outcome and the offspring outcome in DC group (N=184 cycles) and HC group (N=136 cycles). Results: Compared with the HC group, significant increase was observed in the high-quality embryo rate (66.1.2% vs. 55.3%, p=0.037) and implantation rate (49.8% vs. 40.6%, p=0.027) in the DC group. No statistical differences were observed in the pregnant outcome and birth defect of the offspring (p>0.05). Compared with HC, DC was associated with a higher high-quality embryo rate and a higher implantation rate after embryo transfer. Conclusions: No statistical differences were noticed in the offspring conditions between the two culture modes. Taken together, DC may serve as a promising method for IVF-ET.


2009 ◽  
Vol 16 (04) ◽  
pp. 542-549
Author(s):  
FARNOUSH FARZI ◽  
Mona Oudi ◽  
MARZIEH MEHRAFZA ◽  
Zahra Mohammad Tabar ◽  
ALI MIRMANSOURI ◽  
...  

O b j e c t i v e : The aim of this study was to compare the side effects, fertilization rate and pregnancy rate (PR) and duration ofrecovery between Propofol and Thiopental Na after ICSI-vaginal retrieval of oocyte in ART cycle. D e s i g n : This study was a prospective,randomized clinical trial Materials and M e t h o d s : Ninety eight ASA(American Society of Anesthesiologist) physical status I and II womenparticipating in an intracytoplasmic sperm injection) ICSI) program were assessed. All of the patients underwent general anesthesia inductionwith Propofol and Thiopental Na. The first group (49cycles) received 2-2.5mg/kg of Propofol, and the second group (49cycles) received 5mg/kgThiopental during transvaginal oocyte retrieval. An informed consent form was obtained for each patients treatment. Variables under studyincluded: female age, cause and duration of infertiIity^postoperative nausea and vomiting(PONV), heamodynamic changes, mean number ofoocyte retrieved, oocyte metaphase II, embryo cleaved, embryo transferred, embryo quality and pregnancy rate(PR)and duration recovery.Statistical analysis was carried out by using SPSS.10 software and statistical test of T-test and chi-square. R e s u l t s : The PR in Propofol groupwas 18(36.7%) and in Thiopental Na group was 19(38.8%) with no significant differences the mean duration of infertility and weight weren'tstatistically significant. The mean number of oocyte retrieved (metaphase II), embryo cleaved, embryo transferred and embryo quality weren'tsignificant between the two groups. The incidence of nausea in Propofol group in comparison with Thiopental Na group was lower withsignificant differences. The incidence of vomiting between two groups was statistically significant (46.9% vs.28.6% respectively)(P<0.05).between two groups. Duration of recovery in Propofol group was 15+/_3min and in Thiopental Na group was 25+/_5 min that was statisticallysignificant(P<0.05). C o n c l u s i o n s : Propofol offered lower incidence of post operative nausea and vomiting and a quick recovery from anesthesia without any adverse effect on pregnancy outcome. These findings showed that Propofol was a good alternative for Thiopental Na in short timeoperation, like ICSI -vaginal retrieval of oocytes.


2006 ◽  
Vol 85 (1) ◽  
pp. 227.e9-227.e12 ◽  
Author(s):  
Yaakov Bentov ◽  
Eliahu Levitas ◽  
Tali Silberstein ◽  
Gad Potashnik

2005 ◽  
Vol 12 ◽  
pp. S7-S8 ◽  
Author(s):  
M PACE ◽  
A PALAGIANO ◽  
M PASSAVANTI ◽  
C CAMMARANO ◽  
D ROMANO ◽  
...  

2015 ◽  
Vol 7 (3) ◽  
pp. 213-215
Author(s):  
Vineet V Mishra ◽  
Preeti A Goyal

ABSTRACT Objective To describe the approach of transabdominal ultrasound-guided oocyte retrieval in a patient of müllerian anomaly and ovarian malposition. Setting A tertiary referral reproductive medicine unit. Patient A 23-year-old patient with müllerian anomaly (right unicornuate with left rudimentary horn uterus) and ovarian malposition. Intervention Controlled ovarian hyperstimulation, transabdominal ultrasound-guided oocyte retrieval. Main outcome measure Total and mature oocytes retrieved, fertilization rate, embryo number and quality. Result Five oocytes were retrieved transabdominally using percutaneous needle puncture under ultrasound guidance. Conclusion In in vitro fertilization (IVF) protocols, patients with müllerian anomaly with inaccessible ovaries vaginally, transabdominal ultrasound-guided follicular aspiration is a safe and efficacious alternative technique for oocyte retrieval. How to cite this article Mishra VV, Choudhary S, Goyal PA, Aggarwal R. Transabdominal Ultrasound-guided Follicular Aspiration in Case of Müllerian Anomaly with Ovarian Malposition. J South Asian Feder Obst Gynae 2015;7(3):213-215.


2020 ◽  
Vol 37 (12) ◽  
pp. 3039-3049
Author(s):  
Maria Elisabetta Coccia ◽  
Francesca Rizzello ◽  
Savio Wakunga ◽  
Laura Badolato ◽  
Paolo Evangelisti ◽  
...  

Abstract Purpose To evaluate the effectiveness, efficiency, and safety of a transnational gamete donation (TGD) programme based on the shipping of vitrified donor oocytes. Methods A retro-prospective observational study was conducted in the Assisted Reproductive Technology Center of the University Hospital of Florence, Italy. The study population included 622 consecutive donor oocyte cycles. A mean number of 6 vitrified oocytes per couple were shipped from two Spanish biobanks. In the receiving centre, gametes were warmed and inseminated and the subsequent embryo transfer (ET) was performed. The main outcome measurement was LBR. Secondary outcomes included oocyte survival rate, ICSI damage rate, normal fertilization, cleavage, and implantation rate (IR) in both ‘fresh’ and cryotransfer cycles. Results A total number of 3536 mature oocytes were warmed with 81.4% surviving oocytes. 2PN oocytes were 1941 with an ICSI normal fertilization rate of 70.4% and a cleavage rate of 93.4%; 857 day-3 embryos were transferred in 498 women, 63 blastocysts in 44. Couples with at least one vitrified embryo were 181 (32.3%). IR was 25.1% and 33.1% for day-3 ET and blastocyst stage respectively. Crude pregnancy rate and LBR after the first ET were 35.5% and 27% correspondingly with a conservative cumulative LBR of 34% and an optimal LBR of 51.4%. Conclusion Imported vitrified donor oocytes retain their competence and are capable of resulting in ongoing pregnancies and healthy babies in a proportion comparable to other existing systems as egg donation with vitrification/warming in the same laboratory and transnational fresh oocyte donation.


2020 ◽  
Vol 35 (6) ◽  
pp. 1411-1420
Author(s):  
Qi Qiu ◽  
Jia Huang ◽  
Yu Li ◽  
Xiaoli Chen ◽  
Haiyan Lin ◽  
...  

Abstract STUDY QUESTION Does an artificially induced FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? SUMMARY ANSWER An additional FSH bolus administered at the time of hCG trigger has no effect on clinical pregnancy rate, embryo quality, fertilization rate, implantation rate and live birth rate in women undergoing the long GnRH agonist (GnRHa) protocol for IVF/ICSI. WHAT IS KNOWN ALREADY Normal ovulation is preceded by a surge in both LH and FSH. Few randomized clinical trials have specifically investigated the role of the FSH surge. Some studies indicated that FSH given at hCG ovulation trigger boosts fertilization rate and even prevents ovarian hyperstimulation syndrome (OHSS). STUDY DESIGN, SIZE, DURATION This was a randomized, double-blinded, placebo-controlled trial conducted at a single IVF center, from June 2012 to November 2013. A sample size calculation indicated that 347 women per group would be adequate. A total of 732 women undergoing IVF/ICSI were randomized, using electronically randomized tables, to the intervention or placebo groups. Participants and clinical doctors were blinded to the treatment allocation. PARTICIPANTS/MATERIALS, SETTING, METHODS Patients aged ≤42 years who were treated with IVF/ICSI owing to tubal factor, male factor, unexplained, endometriosis and multiple factors were enrolled in this trial. Subjects all received a standard long GnRHa protocol for IVF/ICSI and hCG 6000–10 000 IU to trigger oocyte maturation. A total of 364 and 368 patients were randomized to receive a urinary FSH (uFSH) bolus (6 ampules, 450 IU) and placebo, respectively, at the time of the hCG trigger. The primary outcome measure was clinical pregnancy rate. The secondary outcome measures were FSH level on the day of oocyte retrieval, number of oocytes retrieved, good-quality embryo rate, live birth rate and rate of OHSS. MAIN RESULTS AND THE ROLE OF CHANCE There were no significant differences in the baseline demographic characteristics between the two study groups. There were also no significant differences between groups in cycle characteristics, such as the mean number of stimulation days, total gonadotrophin dose and peak estradiol. The clinical pregnancy rate was 51.6% in the placebo group and 52.7% in the FSH co-trigger group, with an absolute rate difference of 1.1% (95% CI −6.1% to 8.3%). The number of oocytes retrieved was 10.47 ± 4.52 and 10.74 ± 5.01 (P = 0.44), the rate of good-quality embryos was 37% and 33.9% (P = 0.093) and the implantation rate was 35% and 36% (P = 0.7) in the placebo group and the FSH co-trigger group, respectively. LIMITATIONS, REASONS FOR CAUTION This was a single-center study, which may limit its effectiveness. The use of uFSH is a limitation, as this is not the same as the natural FSH. We did not collect follicular fluid for further study of molecular changes after the use of uFSH as a co-trigger. WIDER IMPLICATIONS OF THE FINDINGS Based on previous data and our results, an additional FSH bolus administered at the time of hCG trigger has no benefit on clinical pregnancy rates in women undergoing the long GnRHa protocol in IVF/ICSI: a single hCG trigger is sufficient. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by the National Key Research and Development Program of China (2016YFC1000205); Sun Yat-Sen University Clinical Research 5010 Program (2016004); the Science and Technology Project of Guangdong Province (2016A020216011 and 2017A020213028); and Science Technology Research Project of Guangdong Province (S2011010004662). There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER The trial was registered in the Chinese Clinical Trial Registry (ChiCTR-TRC-12002246). TRIAL REGISTRATION DATE 20 May 2012. DATE OF FIRST PATIENT’S ENROLMENT 10 June 2012.


Sign in / Sign up

Export Citation Format

Share Document